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Abstract
Background: Heritable factors are well known to increase the risk of cancer in families. Known susceptibility genes
account for a small proportion of all colorectal cancer cases. The aim of this study was to identify the genetic
background in a family suggested to segregate a dominant cancer syndrome with a high risk of rectal- and gastric
cancer. We performed whole exome sequencing in three family members, 2 with rectal cancer and 1 with gastric
cancer and followed it up in additional family members, other patients and controls.
Results: We identified 12 novel non-synonymous single nucleotide variants, which were shared among 5 affected
members of this family. The mutations were found in 12 different genes; DZIP1L, PCOLCE2, IGSF10, SUCNR1, OR13C8,
EPB41L4B, SEC16A, NOTCH1, TAS2R7, SF3A1, GAL3ST1, and TRIOBP. None of the mutations was suggested as a high
penetrant mutation. It was not possible to completely rule out any of the mutations as contributing to disease,
although seven were more unlikely than the others. Neither did we rule out the effect of all thousands of intronic,
intergenic and synonymous variants shared between the three persons used for exome sequencing.
Conclusions: We propose this family, suggested to segregate dominant disease, could be an example of complex
inheritance.
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Background
Colorectal cancer (CRC) is the second most common can-
cer type in Sweden and the third most common cancer
type in the western world. Epidemiological studies have
estimated that the risk of developing colorectal cancer in
first-degree relatives of patients diagnosed with cancer is
increased by two to four-fold [1]. Several hereditary syn-
dromes, such as Familial Adenomatous Polyposis (FAP)
and Lynch syndrome, are known where the risk of cancer
development can be as high as 100 %. However, all known
familial CRC syndrome account for less than 5 % of all
colorectal cancer cases. No hereditary cause has been
identified in most of the families with familial cancer. Even
though these families show empirical evidence of an
increased risk of developing cancer, most of them do not
fulfill the criteria for FAP or Lynch syndrome [2]. This is
indicative of additional genes predisposing to cancer
development, which are yet to be discovered. Linkage
studies in familial CRC have been successful in localiz-
ing highly penetrant CRC genes such as APC, MSH2,
MLH1, and recently also GREM1 [3, 4]. More recent
studies using linkage analysis in familial CRC have re-
sulted in various mostly non-overlapping suggested loci.
Only one locus on chromosome 9 has been confirmed in
several studies [5–7]. Other studies have focused on
studying CRC as a complex disease and presented evi-
dence for low penetrant genetic risk factors, each typically
with a very small increased risk of cancer. Till date, 25 var-
iants have been suggested [8]. Next generation sequencing
(NGS) has become a valuable tool in the discovery of can-
didate genes in several studies. So far, this has generated
only a small number of potential CRC predisposing genes
such as POLE, POLD1, and NTHL1 [9, 10]. The likelihood
of identifying high-penetrant genes is increased by using
large pedigrees with familial cancer as exemplified by the
findings of FAN1 [11]. The combination of linkage ana-
lysis and NGS of the target region using large pedigrees
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has also been successful to define BMPR1A and RPS20 as
predisposing genes [12, 13].
We have previously published a linkage study report-
ing a LOD score of 2.1 in a region on chromosome 3q
[14]. One large pedigree (family 242) mostly contributed
to this high LOD score, where a seemingly dominant
predisposition to rectal and/or gastric cancer was ob-
served. We hypothesized that the mixed representation
of rectal and gastric cancer among family members was
due to one predisposing mutation in one gene and per-
formed a whole exome study to test it. Three family
members were chosen for whole-exome sequencing; one
case with gastric cancer at age 63, and two cases with
rectal cancer at age 50 and 40 years of age respectively.
Methods
Family 242
The family segregates early onset rectal- and gastric cancer
over three generations suggesting a dominant inherited
predisposition. In total there were six cases with early-onset
rectal cancer and in total at least four cases with gastric
cancer. Many family members had presented with tubular
adenomas and hyperplastic polyps under surveillance. In
particular, four family members had lesions, which could
be used for coding of affected status in our study. One
(Co-652) had three large tubulovillous adenomas (TVA),
one (Co-692) had four tubular adenomas (TA) and 8
hyperplastic polyps (HP), and one (Co-657) had 5 large
HP. They were all coded as affected in the first linkage
analysis. One family member with gastric cancer (Co-441)
and two relatives with rectal cancer (Co-666 and Co-771)
were used for the initial exome sequencing study
(Table 1).
Samples used in analysis
Exome sequencing of three members from family 242 was
performed along with 30 research samples sequenced for
a different study [15]. The data was used in addition to
MAF to rule out common variants, as these samples used
the same library preparation, same sequencing facility at
the same time. No information was recorded from any
individual patients in this study.
Anonymous exome data from 249 consenting rare
disease patients and relatives from the department of
Clinical Genetics at Karolinska University Hospital, Solna,
Sweden (249 Swedish controls) were used for comparison
of allele frequencies in our analysis. An additional dataset
of 98 cases from 57 high-risk colorectal cancer families,
who had undergone whole-exome sequencing (unpub-
lished data), was also used for comparison. The families
were included for study when they underwent genetic
counseling at the department of Clinical Genetics,
Karolinska University Hospital, Solna (Sweden). Finally, in
total 190 cases from 190 families with at least two gastric
and one colorectal, or at least two colorectal and one gas-
tric cancer cases were used for testing of the candidate gene
SUCNR1. The families were included in studies as part of
the Swedish Colorectal Cancer Low-risk Study, which
included consecutive CRC cases between 2003 and 2009.
The study was undertaken with permission for the
¨Regional research ethics committee in Stockholm, ID´s:
2002/489 (Swedish Colorectal Cancer Low-risk Study)
and 2008/125-31.2 (participants recruited from dept of
Clinical Genetics) and 2012/2106-31.4 (The 249 Swedish
controls). All participants gave written consent to partici-
pate in the studies.
Exome sequencing family 242 and 30 other research
samples
Library preparation was performed with the SureSelect
XT Human All Exon 50 Mb kit. Samples were clustered
on a cBot and sequenced on Illumina HiSeq 2000. The
reads were aligned to the reference genome hg19GRCh37
using BWA [16]. Then, the calculation of mapping and
enrichment statistics were done with Picard [17] and
GATK [18]. The average coverage of samples Co-441,
Co-666, and Co-771, are 41x, 32x, and 35x. And the
percent of bases above 15x are 80.2 %, 72.9 %, and 76.3 %
respectively.
Exome sequencing of 98 familial CRC samples
DNA was quantified using a Qubit Flurometer (Life
Technologies). Sequencing libraries were prepared accord-
ing to the TruSeq DNA Sample Preparation Kit EUC
15005180 or EUC 15026489 (Illumina). Briefly, 1–1.5 ug of
genomic DNA was fragmented using a Covaris (Covaris,
Inc.). Thirty-seven of the DNA samples were fragmented
according to the Covaris 400 bp protocol and 61 samples
were fragmented according to the SureSelect Protocol.
After fragmentation, all samples were subjected to end-
repair, A-tailing, and adaptor ligation of Illumina Multiplex-
ing PE adaptors. An additional gel-based size selection step
was performed for the 37 samples. The adapter-ligated
fragments were subsequently enriched by PCR followed by
purification using Agencourt AMPure Beads (Beckman
Coulter). Exome capture was performed by pre-pooling
equimolar amounts and performing enrichment in 5-
or 6-plex reactions according to the TruSeq Exome
Enrichment Kit Protocol (EUC 15013230). Library size
was checked on a Bioanalyzer High Sensitivity DNA chip
(Agilent Technologies) while concentration was calculated
by quantitative PCR. The pooled DNA libraries were clus-
tered on a cBot instrument (Illumina) using the TruSeq
PE Cluster Kit v3. Paired-end sequencing was performed
for 100 cycles using a HiSeq 2000 instrument (Illumina)
with TruSeq SBS Chemistry v3, according to the manufac-
turer’s protocol. Base calling was performed with RTA
(1.12.4.2 or 1.13.48) and the resulting BCL files were
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filtered, de-multiplexed, and converted to FASTQ
format using CASAVA 1.7 or 1.8 (Illumina). Data have
been analyzed using the bcbb package [19]. After
sequencing, the samples have been aligned to the refer-
ence genome hg19GRCh37 using BWA, sorted and
PCR duplicates were removed with Picard. The calcula-
tion of mapping and enrichment statistics were done
with Picard and GATK. Variants were called using
GATK and followed a best practice procedure imple-
mented at the Broad Institute [20].
Sanger sequencing
The PCR primers were designed using Primer3web [21]
and SimGene Primer3 [22]. The sequences were visual-
ized and analyzed using FinchTV [23] and CodonCode
Aligner [24].
Table 1 Segregation test of 34 variants in family 242
Chrom:Positiona Ref Alt Gene dbSNP 1000Gb Co-441 Co-634 Co-666 Co-667 Co-771 Co-652 Co-692 Co-657
1:235577776 C T TBCE rs62620041 0.0023 C/T C/C C/T C/T C/T C/C C/C C/C
2:29295186 C T C2orf71 rs75276619 0.01 C/T C/T C/T C/C C/C C/C C/T C/C
2:155555406 A G KCNJ3 rs16838016 0.0032 A/G A/A A/G A/G A/G A/G A/A A/G
2:169870004 G A ABCB11 rs11568361 A/G G/G A/G A/G A/G A/G G/G G/G
3:137786409 A C DZIP1L A/C A/C A/C A/C A/C A/C A/A A/C
3:142542415 C T PCOLCE2 rs147612568 0.0014 C/T C/T C/T C/T C/T C/T C/C C/T
3:151171329 G T IGSF10 rs143721392 G/T G/T G/T G/T G/T G/T G/T G/T
3:151598890 T C SUCNR1 C/T C/T C/T C/T C/T C/T C/T C/T
4:13590380 A G BOD1L1 rs140964488 0.0009 A/G A/G A/G A/A A/G A/A A/G A/A
4:22440018 C G GPR125 rs144997202 0.0005 C/G C/G C/G C/C C/G C/G C/G C/C
4:25849449 G A SEL1L3 A/G A/G A/G G/G A/G A/G A/G G/G
7:141765172 A T MGAM A/T A/T A/T A/A A/T A/A A/A A/A
9:107331452 G A OR13C8 A/G A/G A/G A/G A/G G/G G/G G/G
9:111947836 GGA - EPB41L4B GGA/- GGA/- GGA/- GGA/- GGA/- GGA/GGA GGA/GGA GGA/GGA
9:139369066 G A SEC16A rs148167113 0.01 A/G A/G A/G A/G A/G A/G A/G A/G
9:139401233 C T NOTCH1 rs61751543 0.01 C/T C/T C/T C/T C/T C/T C/T C/T
10:5931230 C T ANKRD16 rs3750659 0.06 C/T C/T C/T C/C C/T C/C C/C C/C
11:130784886 T C SNX19 rs117260465 0.01 C/T C/T C/T T/T C/T T/T C/T T/T
12:10954583 A T TAS2R7 rs139604652 0.0032 A/T A/T A/T A/T A/T A/A A/T A/A
12:109617728 A G ACACB rs16940029 0.08 A/G A/A A/G A/A A/G A/A A/G A/G
16:14029033 G A ERCC4 rs1800067 0.03 A/G G/G A/G A/G A/G G/G G/G A/G
16:15818842 A G MYH11 rs16967510 0.02 A/G A/A A/G A/A A/G A/G A/A A/G
16:22826046 T G HS3ST2 rs189013090 0.01 G/T T/T G/T G/T G/T T/T T/T G/T
17:62028920 C G SCN4A rs41280102 0.01 C/G C/C C/G C/C C/G G/G C/G C/G
18:67721492 G C RTTN rs34717557 0.01 C/G G/G C/G G/G C/G C/G G/G C/G
18:67836115 G T RTTN rs34353615 0.01 G/T G/G G/T G/G G/T G/T G/G G/T
18:72343156 A G ZNF407 rs75994611 0.01 A/G A/A A/G A/A A/G A/G A/A A/G
19:3834863 C T ZFR2 rs61747120 0.04 C/T C/C C/T C/C C/T C/T C/T C/T
22:30733787 C T SF3A1 C/T C/T C/T C/T C/T C/T C/T C/C
22:30951208 C T GAL3ST1 rs139452633 0.0005 C/T C/T C/T C/T C/T C/T C/T C/C
22:38111897 C T TRIOBP rs143157673 0.0018 C/T C/T C/T C/T C/T C/T C/T C/C
22:46653273 C T PKDREJ rs147180698 C/T C/C C/T C/C C/T C/T C/T C/C
X:107844666 G T COL4A5 rs34077552 0.01 G/T G/G G/T G/T T/T G/T G/T G/T
X:119293216 - G RHOXF2 -/G −/− -/G -/G -/G -/G -/G -/G
List of 34 rare variants after filtering all non-exonic variants, synonymous variants, variants presenting in the 30 breast cancer cases [15], and variants with allele
frequency in 1000Genomes more than 20 %
aGRCh37 (hg19) coordinates
b1000 Genomes version April 2012 (hg19)
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Mutation annotation
The output mutations in variant call format (vcf ) were
annotated using ANNOVAR [25], which generated an
Excel-compatible file with gene annotation, amino acid
change annotation, dbSNP identifiers [26], 1000 Ge-
nomes Project allele frequencies [27], and functional
prediction from SIFT [28], PolyPhen2 [29], LRT [30],
MutationTaster [31], PhyloP [32], and GERP++ [33].
Results
Whole exome-sequencing was used to analyze the three
patients from family 242 together with 30 other research
samples for a separate study. All samples were computa-
tionally analyzed using a process to generate candidate
mutations to be causative in family 242. All mutations
shared between the three family members were selected,
all with a MAF > 20 % in 1000Genomes (1000G), all
non-exonic and synonymous variants, and all variants
present in more than one of the 30 other research sam-
ples were excluded. After this filtering 34 mutations/var-
iants remained as candidates (Table 1). Interestingly, not
only the region on chromosome three showed linkage to
cancer in the family but also several other chromosomal
regions (Table 1). We used another five relatives from
this kinship for Sanger sequencing of the 34 variants to
find out the correlation with disease. The outcome for
each family member is shown in Table 1.
Of the five family members tested for the 34 variants,
only two (Co-634 and Co-667) had cancer, and both had
rectal cancer and were therefore considered to be gene
carriers. Using this data allowed us to remove 22 of the
34 variants. In detail, 15 variants were excluded, since
they were not shared by Co-634. Seven more were ex-
cluded since they were not shared by Co-667 (Tables 1
and 2). Thus, 12 candidate mutations in four chromo-
somal regions remained as predisposing gene mutation
candidates. All twelve variants were either unique (not
present in 1000G) or extremely rare (1000G MAF <
1 %). The EPB41L4B has an in-frame deletion of three
bases in exon 23, and all other mutations were missense
mutations. Five of them had already been reported in
dbSNP. The mutation frequency of these 12 mutations
was compared to 98 Swedish familial CRC cases, 249
Swedish controls, and MAF in 1000G. Only three of the
12 variants were present among 98 familial CRC cases
(in the genes SEC16A, NOTCH1 and TAS2R7) (Table 2).
However, none of those three segregated with the dis-
ease in the other families, and thus, cannot be regarded
as high-risk gene-mutations.
Next, we used our 98 CRC cases to search for other
mutations in the 12 genes. We excluded all non-exonic
and synonymous variants, all variants with MAF > 20 %,
and those without any predicted pathogenic effect, and
variants with a frequency less than the Swedish controls.
After this, 36 variants among 11 genes remained (Table 3).
No additional mutation was seen in SUCNR1. To find out
if SUCNR1 could represent a high-penetrant gene, 190
samples from families with both colorectal and gastric
cancer were used for sequencing of the whole gene
without finding any mutation. The SUCNR1 functions as
a receptor for the citric acid cycle intermediate succinate,
involved in the renin-angiotensin system [34] and from its
function less likely to be associated with a colorectal can-
cer risk. Thus, we could not find any further support for
SUCNR1 as a candidate gene. One interesting candidate
variant was a frameshift deletion in the TRIOBP gene but
it did not segregate in a family. Another variant was a
non-frameshift deletion in the SEC16A gene but it did not
segregate with cancer in the family either. One other po-
tential mutation was a stop-gain in the DZIP1L gene but it
also did not segregate in the family. All other 33 mutations
were non-synonymous SNPs. Analysis in other families
showed segregation only in one family, where a variant in
the gene IGSF10 was shared between two affected rela-
tives. However, the same variant was also found in three
other families where it did not segregate with disease.
Thus, none of the 12 genes was supported as being a
high-penetrant gene variant based on the analysis of the
98 families colorectal cancer cases (Table 3).
We considered the known functions of the genes to
predict if they were likely CRC genes. We also consid-
ered the predicted pathogenicity of each conceptual
non-synonymous amino acid change. All 12 variants but
one (SEC16A) were predicted to have a pathogenic effect
based on at least one predictor algorithm (Table 2). The
Table 2 Twelve candidate mutations in family 242, and in-silico
functional prediction




F1 F2 F3 F4 F5
DZIP1L C T D N N
PCOLCE2 rs147612568 0.0014 C D D D D
IGSF10 rs143721392 C D D D N
SUCNR1 C D D D N
OR13C8 C T B N -
EPB41L4B 0.002 Non-frameshift
deletion
SEC16A rs148167113 0.01 0.0153 0.004 - - - - -
NOTCH1 rs61751543 0.01 0.0204 0.01 C T D D D
TAS2R7 rs139604652 0.0032 0.0051 C D D N N
SF3A1 C T P D D
GAL3ST1 rs139452633 0.0005 0.004 C D D D D
TRIOBP rs143157673 0.0018 N - P - -
F1, Phylop; C, Conserved; N, Not conserved
F2, SIFT; T, Tolerated; D, Deleterious
F3, Polyphen2; D, Probably damaging; P, Possibly damaging; B, Benign
F4, LRT; N, Neutral; D, Deleterious
F5, MutationTaster; N, Polymorphism; D, Disease causing
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Table 3 Thirty-six mutations in the twelve genes that can be found in 98 CRC cases
Chrom:Positiona Ref Obs dbSNP Func Gene Exonic function 1000G 249 patients 98 CRC
casesb
F1 F2 F3 F4 F5 c d e
3:137786496 G A exonic DZIP1L stopgain SNV 0.0051 N - - N D 1
3:137790616 C T rs150466957 exonic DZIP1L ns SNV 0.0009 0.0051 N D P N N 1
3:137813726 G A rs148594666 exonic DZIP1L ns SNV 0.0009 0.0051 C T P N N 1
3:142539852 C T exonic PCOLCE2 ns SNV 0.002 0.0051 C T B D N 1
3:142548681 C T rs140721173 exonic PCOLCE2 ns SNV 0.0009 0.002 0.0051 N T B D D 1
3:151163838 T C rs34114908 exonic IGSF10 ns SNV 0.01 0.01 0.0357 N D B N N 2 3
3:151165241 G C rs142202060 exonic IGSF10 ns SNV 0.0005 0.004 0.0102 C D P N N 1
3:151165532 G C rs35667704 exonic IGSF10 ns SNV 0.0037 0.0141 0.0153 N D P N N 1 1
3:151166124 A G rs146828199 exonic IGSF10 ns SNV 0.0051 C D D N D 1
9:107332377 T A rs76017116 exonic OR13C8 ns SNV 0.01 0.004 0.0153 C D B D D 3
9:111954616 C T rs199718023 exonic EPB41L4B ns SNV 0.0051 C D B N N 1
9:111954622 C T rs201059767 exonic EPB41L4B ns SNV 0 C D B N N 1
9:112029768 C T exonic EPB41L4B ns SNV 0.0051 C T B N - 1
9:112082510 C T rs117569740 exonic EPB41L4B ns SNV 0.14 0.1124 0.1531 C D B - - 8 4 14
9:139345847 G A rs45519739 exonic SEC16A ns SNV 0.01 0.0153 1 1
9:139348749 G A rs79974534 exonic SEC16A ns SNV 0.01 0.0141 0.0306 1 1 2
9:139360781 G A rs199798606 exonic SEC16A ns SNV 0.004 0.0051 1
9:139368953 G A rs3812594 exonic SEC16A ns SNV 0.16 0.2048 0.2653 9 9 17
9:139369066 G A rs148167113 exonic SEC16A ns SNV 0.01 0.004 0.0153 1 2
9:139369091 C T rs11788702 exonic SEC16A ns SNV 0.0005 0.0051 1
9:139369408 C T rs200238338 exonic SEC16A ns SNV 0.0051 1
9:139369816 G C rs200394508 exonic SEC16A ns SNV 0.0204 1 3
9:139370955 del9 - exonic SEC16A non-frameshift deletion 0.008 0.0153 1 2
9:139401233 C T rs61751543 exonic NOTCH1 ns SNV 0.01 0.01 0.0204 C T D D D 2 2
9:139409775 C T rs201077220 exonic NOTCH1 ns SNV 0.0009 0.0051 C T B - D 1
12:10954258 C T rs619381 exonic TAS2R7 ns SNV 0.07 0.0884 0.1173 N T D N N 1 5 12
12:10954583 A T rs139604652 exonic TAS2R7 ns SNV 0.0032 0.0051 C D D N N 1
22:30742345 T G exonic SF3A1 ns SNV 0.0102 C T P D D 2
22:30953280 C T rs55674628 exonic GAL3ST1 ns SNV 0.01 0.0161 0.0204 C T B N N 2 3
22:38120338 G A exonic TRIOBP ns SNV 0.0051 N - D - - 1
22:38120542 C T rs142024473 exonic TRIOBP ns SNV 0.03 0.0201 0.0459 C - P - - 1 1 6
22:38120985 A G exonic TRIOBP ns SNV 0.0051 N - D - - 1
22:38121040 C T rs41296243 exonic TRIOBP ns SNV 0.01 0.0201 0.0306 N - P - - 2 1 2
22:38121795 C T rs200359708 exonic TRIOBP ns SNV 0.0018 0.0051 C - D - - 1
22:38122414 AG - exonic TRIOBP frameshift deletion 0.0051 2
22:38129388 G A rs34066624 exonic TRIOBP ns SNV 0.0023 0.008 0.0204 C - - - - 1 3
aGRCh37 (hg19) coordinates
b1000 Genomes version April 2012 (hg19)
cNumber of families where only one individual was sequenced and had a mutation
dNumber of families where at least two individuals were sequenced and the mutation segregated
eNumber of families where at least two individuals were sequenced and the mutation did not segregate
F1, Phylop; C, Conserved; N, Not conserved
F2, SIFT; T, Tolerated; D, Deleterious
F3, Polyphen2; D, Probably damaging; P, Possibly damaging; B, Benign
F4, LRT; N, Neutral; D, Deleterious
F5, MutationTaster; N, Polymorphism; D, Disease causing
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SUCNR1 we already excluded as a candidate high-risk
mutation (above). The genes PCOLCE2, SEC16A,
TAS2R7, and TRIOBP were considered less likely to be
associated with increased CRC risk based on established
functions. The Pro-collagen C-endopeptidase enhancer
(PCOLCE2), has no known relation to cancer [35]. The
S. Cerevisiae homolog (SEC16A), is a peripheral mem-
brane protein and is required for protein transport from
ER to Golgi [36]. The Taste receptor (TAS2R7) is a
member of the G protein–coupled receptor superfamily
and specifically expressed in taste receptor cells [37].
Trio- and F-actin-binding protein (TRIOPB) has been
related to autosomal recessive deafness syndromes [38].
The linkage study performed previously used also those
with advanced polyps as affected in analysis [14]. We tested
also in this study to use polyps in relatives to select among
the genes. The patient (Co-652) with three tubulovillous
adenomas (all in rectum and two with high-degree dyspla-
sia) at the first colonoscopy, was highly likely to be a gene
carrier. Making this assumption, two more genes (OR13C8,
EPB41L4B) could be excluded. The patient (Co-692) with
four small tubular adenomas at an age of 75 was a less clear
case. The adenomas were 2 mm each and located in the
ascending, transverse and descending colon, all with low-
degree dysplasia, with an additional one in rectum with
high-degree dysplasia. To consider this individual as
affected and a gene carrier would exclude one more candi-
date gene (DZIP1L). Finally, if also the patient (Co-657)
with five hyperplastic polyps at an age of 73 years was
considered a gene carrier, yet another three genes (SF3A1,
GAL3ST1, TRIOBP) could be excluded.
Discussion
Many pedigrees in families seeking counseling about their
risk of cancer show a pedigree of typical dominant high-
penetrant disease. Family 242 seemed to segregate a risk of
rectal as well as gastric cancer and perhaps other cancers
among the family members. The pedigree suggested a mu-
tation in a highly penetrant predisposing gene. When the
family was tested negative for known inherited syndromes
it was included in studies to localize new disease genes.
First, linkage analysis was employed assuming a dominant
mode of inheritance and this resulted in a candidate region
on chromosome 3 [14]. The region was quite large and it
was not possible at the time to perform sequencing of all
genes in the region. Only a limited number of candidate
genes were studied without finding a clear mutation [14].
When massively parallel sequencing (MPS) became feas-
ible we decided to study the family further and performed
exome sequencing for three family members. First, all
genes in the region on chromosome 3 was studied, without
finding any clear candidate gene. Next, the whole exome
was studied. It was clear that the three studied family
members shared several chromosomal regions (Table 1)
and not just the one we had detected in our linkage study.
When studying the linkage data again we could see that
linkage was not excluded but did not generate a high
enough LOD score to be considered candidates. We could
identify up to five or even 12 different genes and muta-
tions, which all could have contributed more or less to the
development of tumors in this family. There was no evi-
dence to directly pinpoint one of them, and there was at
the same time some evidence to support the conclusion
that none of the mutation would be associated with a high
risk, and being high penetrant.
Several explanations for our findings are possible.
First, some issues could be related to failures in inter-
pretation of MPS data. How the sequences are aligned
depends on the algorithm used. Different algorithms or
parameters used at different sequencing centers may re-
sult in different alignments and different variants that
are called, especially in the case of insertions or dele-
tions. Old sequence processing workflow may not be
able to detect large deletions (more than 10 bps) in a
correct way. It is possible that a deletion could have
been interpreted as several different point mutations.
We could also have missed a mutation by exclusion of
intronic, intergenic and synonymous mutations. How-
ever, it would have been very difficult to functionally
prove the association of such variants with the disease.
Second, we could have used the wrong individuals for
our first experiment. In the case one of the three is
actually a phenocopy, or if there are two traits, one with
high-penetrant gastric cancer and one with high-
penetrant rectal cancer, it would have been missed in the
analysis. Considering all patients with gastric or rectal
cancer as affected is quite safe and in particular when the
age of onset is low (which was the case for all rectal
cancers). The use of advanced adenomas at an early age is
also frequently used in studies as substitute for colorectal
cancer. The ages of onset of gastric cancer in our study
were 63, 63, 72 and 74 respectively, why it was reasonable
to assume our case of gastric cancer first sequenced (aged
63) as affected in our hypothesis of one gene – two
diseases. It is possible that instead of one high-penetrant
gene, there is a polygenic mode of inheritance where more
than one mutation could have contributed to the develop-
ment of both gastric and rectal cancer. It is also possible
that there are two different low-penetrant genes for gastric
and rectal but with same or different modifying gene
mutations among family members.
Previous linkage studies have identified several candi-
date regions on different chromosomes, but the only one
in the present study, which resembles any of the published
regions, is 9q [6, 7, 14, 39–41]. The region identified in
the present study (the variants in the genes OR13C8,
EPB41L4B, SEC16A and NOTCH1), is just proximal to
that region on 9q. It is possible that the published locus
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and the one in the present study are really the same and
that it holds a modifier gene acting only with the rectal
cancers and not on the gastric cancer. If this is the case
the gene of interest here would be the NOTCH1 or an-
other gene within the same locus.
Of the 12 candidate variants found in the family 242,
seven were less likely due to our analysis above. This means
that there are at least five genes as candidates to have
contributed to the disease in the family (DZIP1L, IGSF10,
NOTCH1, SF3A1, GAL3ST1). The NOTCH1 gene is well
known to be involved in cancer. The gene has been
suggested to be involved specifically in both colorectal and
gastric cancer, although, so far it has not been found to
confer an increased risk [42, 43]. The NOTCH1 variant in
our family was found in three other families, where it did
not segregate. This does not exclude an effect, but does not
suggest it to be high penetrant. The other four candidate
mutations showed to be mutated in several of the 98 famil-
ial colorectal cancer cases. However, none was suggested to
be a high-penetrant mutation based on segregation analysis
in this dataset described above. The human Iguana gene
DZIP1L has been suggested to be part of the Hedgehog
signaling pathway, which is often activated in gastric cancer
but not often in colorectal cancer [44, 45]. The GAL3ST-2
has been shown to be involved in CRC and gastric cancer
[46, 47] while GAL3ST-1 has only been suggested to be
involved in ovarian cancer [48]. The IGSF10 gene has not
been described in relation to colorectal or gastric cancer
but is a gene involved in differentiation and developmental
processes, and possibly involved in rat osteosarcomas [49].
The gene SF3A1 was studied in relation to CRC adenomas
without finding any correlation to this gene [50].
Conclusion
We did not find any clear high-risk gene mutation to
explain the seemingly high risk of rectal and gastric cancer
in this family. We identified 12 candidate genes, none was
supported as high penetrant, suggesting a complex inherit-
ance. Five of the genes (DZIP1L, IGSF10, NOTCH1,
SF3A1, GAL3ST1) were more likely than the other seven.
The gene best known to be related to cancer was the
NOTCH1. Further studies are needed to find out more
about these variants and other gene variants possibly
contributing to the increased cancer risk in this family.
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